Get started
Author

Katharine C. Lai

Observed name: Katharine Lai
ORCID: 0000-0003-4842-8041
Observed ORCID: 0000-0003-4842-8041
OpenAlex ID: A5086428809
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
2010 · Yelena V. Kovtun, Charlene A. Audette, et al. · Cancer Research · 274
Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
2011 · Brenda A. Kellogg, Lisa Garrett, et al. · Bioconjugate Chemistry · 221
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
2013 · Jutta Deckert, Peter U. Park, et al. · Blood · 94
IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
2018 · Yelena Kovtun, Paul Noordhuis, et al. · Molecular Cancer Therapeutics · 77
Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
2020 · Eshita Khera, Cornelius Cilliers, et al. · Neoplasia · 58
PDF
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
2018 · Michael L. Miller, Manami Shizuka, et al. · Molecular Cancer Therapeutics · 57
PDF
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
2019 · Stuart W. Hicks, Chiara Tarantelli, et al. · Haematologica · 41
PDF
A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
2016 · Rajeeva Singh, Yulius Y. Setiady, et al. · Molecular Cancer Therapeutics · 40
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
2017 · Stuart W. Hicks, Katharine C. Lai, et al. · Neoplasia · 34
PDF
Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody–Drug Conjugates (ADCs)
2019 · Emily E. Reid, Katie E. Archer, et al. · ACS Medicinal Chemistry Letters · 20
Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
2020 · Adnan O. Abu-Yousif, Donna Cvet, et al. · Molecular Cancer Therapeutics · 17
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay
2015 · Katharine C. Lai, Jutta Deckert, et al. · Pharmaceutical Research · 11
Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies
2018 · Adnan O. Abu-Yousif, Bret M. Bannerman, et al. · Molecular Cancer Therapeutics · 9
Abstract 45: In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload
2017 · Katharine C. Lai, Asli Muvaffak, et al. · Cancer Research · 5
MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.
2024 · Melissa Lynne Johnson, Timothy F. Burns, et al. · Journal of Clinical Oncology · 4
PDF
Abstract 2830: Antibody and linker selection for the anti-CD37 antibody-maytansinoid conjugate IMGN529 for the treatment of B-cell malignancies
2011 · Peter U. Park, Yong Yi, et al. · Cancer Research · 4
Abstract 2900: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates
2018 · Rui Wu, Cristina Gavrilescu, et al. · Cancer Research · 2
Abstract 4504: Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia
2015 · Katharine C. Lai, Prerak Shah, et al. · Cancer Research · 1
Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).
2013 · Rajeeva Singh, Nathan Fishkin, et al. · Molecular Cancer Therapeutics · 1
Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.
2011 · Katharine C. Lai, Hans K. Erickson, et al. · Molecular Cancer Therapeutics · 1
Supplementary Methods from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
2023 · Rajeeva Singh, Yulius Y. Setiady, et al.
Supplementary Figures from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
2023 · Rajeeva Singh, Yulius Y. Setiady, et al.
Supplementary Table from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
2023 · Rajeeva Singh, Yulius Y. Setiady, et al.
Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
2023 · Adnan O. Abu-Yousif, Donna Cvet, et al.
Data from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
2023 · Adnan O. Abu-Yousif, Donna Cvet, et al.
Works count: 39
Citation count: 971
H-index: 11
I10-index: 12
Year
Topic
Type